#ESMO26: Antoni Ribas receives the 2026 ESMO Lifetime Achievement Award for his significant contributions to #CancerResearch and #CancerImmunotherapy, which have led to groundbreaking therapies becoming part of #ClinicalPractice.
➡️ https://www.esmo.org/insights-by-esmo/all-news/understanding-non-response-to-cancer-immunotherapy-is-key?utm_source=twitter&utm_medium=social&utm_campaign=ESMO-WW-COM-SocialMediaOrganic-NewsInsights-social-twitter-20261023
#InsightsbyESMO
1759 views · 22 likes · 9 reposts · 2 replies
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org- Annie Wong 黃毅敏@anmwongNZ
@myESMO Congratulations!! Little NZ got its anti-PD1 funded for melanoma in 2016 after he and Charlie Balch met with our health minister after a talk at a NZ conference. We are so grateful 🙏🙏🙏Talk about advocacy in action!
- MeDucation@MeDucationai
@myESMO So well deserved. His lab's finding that JAK1/JAK2 loss-of-function mutations let melanoma escape PD-1 blockade is still one of the clearest lessons trainees get on acquired immunotherapy resistance.
Source: ESMO - Eur. Oncology · x.com